Drug Approval | May 07, 2024
Caplin Point gets Colombia approval for Softgel Capsules
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Subscribe To Our Newsletter & Stay Updated
